This is the first systematic review and meta-analysis of studies addressing the prognostic impact of atrial fibrillation in the setting of myocardial infarction. In this meta-analysis of 43 studies involving 278 854 patients, atrial fibrillation was associated with at least a 40% increase in the risk of mortality among patients with myocardial infarction, regardless of the timing of the atrial fibrillation. This worse prognosis persisted even after the studies adjusted for age, diabetes mellitus, hypertension, prior myocardial infarction, heart failure, and coronary revascularization. These findings indicate that atrial fibrillation can no longer be considered a trivial event during the acute phase of myocardial infarction. Research is needed to evaluate potential strategies and interventions to reduce this risk. See p 1587.
Incidence of Sudden Cardiac Death in National Collegiate Athletic Association Athletes
This report more accurately estimates the incidence of sudden cardiac death (SCD) in athletes using improved methodology compared with previous studies. It demonstrates an overall rate of SCD of 1:43 000, with some subpopulations showing a risk of SCD as high as 1:3000. The rate of SCD has been commonly cited as 1:200 000. From a clinical perspective, this is critically important information. The preparticipation examination, or sports physical, is a core part of the practice of sports medicine and primary care physicians alike. The purpose of the preparticipation examination, according to the latest AHA scientific statement, is to identify conditions that may lead to SCD. The current recommendation of the AHA is that this is best done, in the United States, by the use of a directed history and physical exam. There is increasing evidence that this strategy is neither effective nor cost-effective. In other countries, an ECG is a routine part of a sports physical, or in some cases a well-child visit. The information presented in this report will inform the ongoing discussion about SCD in young people and how best to prevent it. There may be subpopulations of athletes or young people in which screening with an ECG by use of modern interpretation criteria would be highly cost-effective, and others in which it would not. This report will have significant ramifications for clinical practice as we strive to understand how to best use our resources, fulfill the primary objective of the sports physical, prepare for sudden cardiac arrest, and ultimately prevent SCD. See p 1594.
Associations Between Outpatient Heart Failure Process-of-Care Measures and Mortality
Heart failure (HF) is a chronic progressive disease that results in substantial morbidity, mortality, and expenditure of healthcare resources. Measuring and improving the quality of HF care is of high priority. Assessment of care quality has focused on the development and use of process-based performance measures, with the assumption that these process measures are associated with clinical outcomes. This association, however, has not previously been evaluated for current and emerging outpatient HF measures. In the present study, we used data from the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF) to examine the relationships between adherence to several HF process measures and clinical outcomes. Performance on 7 HF process measures and 2 summary measures was collected at baseline in patients from 167 US outpatient cardiology practices, with patients followed up for 24 months. Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use, ␤-blocker use, anticoagulant therapy for atrial fibrillation, cardiac resynchronization therapy, implantable cardioverter-defibrillators, and HF education were each independently associated with improved 24-month survival, whereas aldosterone antagonist use was not. The all-or-none and composite care summary measures were also independently associated with improved survival. Each 10% improvement in composite care was associated with a 13% lower odds of 24-month mortality. This study suggests that current and some emerging outpatient HF process measures are positively associated with patient survival. Given the substantial burden of HF, the availability of well-validated process measures to accurately assess and improve the care of patients with HF is critical. See p 1601.
Meta-Analysis: Impact of Drug Class on Adherence to Antihypertensives
More than half of US individuals with hypertension continue to have blood pressure above recommended levels, and poor adherence to antihypertensives remains an important cause of poor blood pressure control. Observational studies suggest that there may be important differences in adherence to antihypertensives in distinct drug classes. Yet, the literature describing the association between drug class and adherence is characterized by a wide variety of patient populations, drug class comparisons, and definitions of adherence. This heterogeneity has made it difficult to make firm conclusions about the clinical relevance of differences in adherence according to drug class. Accordingly, we performed a meta-analysis to determine the impact of antihypertensive drug class on adherence to blood pressure medications. We found that there was a significant relationship between adherence and antihypertensive drug class. Compared with patients prescribed diuretics and ␤-blockers, the drug classes associated with the lowest adherence, patients prescribed angiotensin II receptor blockers were approximately twice as likely to have good adherence. Overall, angiotensin-converting enzyme inhibitors appeared to have the second-best level of adherence, followed by calcium channel blockers, although insufficient data were available for definitive rankings. Our findings demonstrate that it is important for clinicians to pay attention to adherence regardless of drug class because adherence was suboptimal for all drug classes and that clinicians should pay special attention to adherence in patients who are prescribed diuretics and ␤-blockers. See p 1611.
Clinical Benefit of Statin Pretreatment in Patients Undergoing Percutaneous Coronary Intervention: A Collaborative Patient-Level Meta-Analysis of 13 Randomized Studies
In this collaborative patient-level meta-analysis of 13 randomized, controlled trials (nϭ3341 patients), we demonstrated that short-term pretreatment with high-dose statins reduces the incidence of periprocedural myocardial infarction and early major adverse cardiac events in patients undergoing percutaneous coronary intervention. This outcome improvement was irrespective of clinical presentation, chronic statin therapy, or antithrombotic treatment, and was more pronounced in patients with high baseline inflammatory status. Our April 19, 2011 results strengthen the concept that the clinical benefit provided in the short-term by high-dose statins is due to pleiotropic effects. These data suggest that a strategy of early initiation of high-dose statins should be implemented routinely in patients who are candidates for percutaneous coronary intervention, and guideline committees should consider updates to incorporate this novel strategy for periprocedural percutaneous coronary intervention prevention of ischemic events. See p 1622.
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Nkx2-5 Represses Gata1 Gene Expression and Modulates the Cellular Fate of Cardiac Progenitors During Embryogenesis
The heart is the first organ to develop during embryogenesis. Genetic perturbations during development result in congenital heart disease, which is associated with considerable morbidity and mortality. To enhance our understanding of congenital heart disease, intense interest has focused on the definition of genetic networks that govern stem cells to form lineages such as the heart, vasculature, or blood. In the present study, we examined the hypothesis that Nkx2-5, in a context-dependent manner, regulates the formation of the heart and blood lineages. These studies advance our understanding of the molecular regulation of cardiac stem cells and have implications for congenital heart disease and cardiac regeneration. See p 1633.
Persistent Racial Disparities in Survival After Heart Transplantation
Racial and ethnic minority patients have poorer clinical outcomes in many forms of heart disease. We assessed outcomes among 39 075 initial heart transplant recipients categorized by racial and ethnic groups. Nonwhite transplant recipients had a higher clinical risk profile at baseline than white recipients. Black heart transplant recipients had 34% higher mortality than whites, which remained significant even after adjustment for recipient, transplant, and socioeconomic factors. Mortality for other minority groups was not different from that of whites. Black patients were more likely to die of causes associated with underimmunosuppression (cardiovascular causes or graft failure) and less likely to die of causes associated with overimmunosuppression (infection or malignancy). Despite the increased attention to mortality disparities present among black patients-in health care broadly and cardiovascular care specifically-the disparity in mortality between blacks and whites after heart transplantation remained essentially unchanged over time. Future investigation is needed into potential causes of the higher mortality among black heart transplant recipients, which appears to be due to less effective immunosuppression. Novel methods of assessing immunosuppression, from both immunologic and sociomedical perspectives, may be important. See p 1642.
